your market intelligence analyst
Search Results
Edit Save
103 results
Immuno-Oncology News 10/01/2019 11:37
Opdivo (nivolumab) continues to increase the long-term overall survival of patients with advanced non-small cell lung cancer (NSCLC) compared to the chemotherapy Taxotere (docetaxel), according to pooled data from two Phase 3 trials. The findings were presented in an oral presentation, titled “Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel […]. .
Immuno-Oncology News 09/27/2019 08:57
The U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Mateon‘s OT101 as a therapy for diffuse intrinsic pontine glioma (DIPG), a difficult-to-treat brain tumor that affects children. The designation is designed to accelerate the development of therapies that can improve the management of serious or life-threatening conditions affecting less than 200,000 […]. .
Immuno-Oncology News 09/24/2019 10:45
A combination of ilixadencel plus Sutent (sunitinib) is showing promising efficacy in patients with kidney cancer that has spread to other organs, according to topline data from a Phase 2 trial. Ilixadencel, Immunicum‘s lead candidate for the treatment of different types of solid tumors, is a cancer vaccine based on the use of dendritic cells […]. .
Immuno-Oncology News 09/20/2019 09:52
Magrolimab, an experimental antibody developed by Forty Seven, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The designation is given to therapies that show potential to treat serious health conditions, and is intended to accelerate their development and approval […]. .
Immuno-Oncology News 09/13/2019 11:01
Immunotherapies have shown little efficacy in brain cancers due to their inability to cross the blood-brain barrier. Now, however, researchers have developed a new nanotechnology approach that allowed immune checkpoint inhibitors to enter the brains of mice with glioblastoma. The approach increased the amount of immune cells reaching the tumor and improved the survival of […]. .
Immuno-Oncology News 09/11/2019 08:42
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BXCL701, one of BioXcel Therapeutics’ lead immunotherapies for the treatment of acute myeloid leukemia (AML). Orphan drug status is given to investigative treatments for rare diseases, defined in the U.S. as disorders that affect fewer than 200,000 people. The designation comes with […]. .
Immuno-Oncology News 09/04/2019 10:48
Cellectar Biosciences announced that a second and higher dose of its investigational radiotherapeutic compound, CLR 131, was cleared for use in its ongoing CLOVER-2 study in children with advanced solid cancers, lymphomas, and brain tumors. The independent committee overseeing the trial recommended moving to a higher dose after the first dose tested was found safe […]. .
Immuno-Oncology News 08/28/2019 12:03
A $102.2 million Pelotonia donation will help establish an institute at Ohio State University (OSU) that will focus exclusively on groundbreaking immuno-oncology therapies and cures for cancer. Disbursed over five years, the funds will support research to be conducted by the Pelotonia Institute for Immuno-Oncology (PIIO) at the OSU Comprehensive Cancer Center — Arthur G. James […]. .
Immuno-Oncology News 08/27/2019 11:50
Immune checkpoint inhibitors targeting the PD-L1 molecule appear to activate immune cells called natural killer (NK) cells, a new study says. This finding may explain why some tumors are responsive to these checkpoint inhibitors even when the PD-L1 checkpoint protein isn’t expressed. The new study, “The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors […]. .
Immuno-Oncology News 08/21/2019 08:36
A combination of Leap Therapeutics‘ investigational therapy DKN-01 plus Keytruda (pembrolizumab) led to "highly encouraging" responses and survival outcomes in a population of advanced esophagogastric cancer patients with elevated levels of the Dickkopf-1 (DKK1) protein, according to preliminary results of a Phase 1 clinical trial.
Immuno-Oncology News 08/20/2019 10:11
INmune Bio’s therapy candidate INB03 is well-tolerated and has shown signs of activity in patients with advanced cancers, according to preliminary findings from a Phase 1 clinical trial. The early results were revealed recently at the Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit, in the presentation, “Targeting Soluble TNF to Improve Efficacy of Combination Immunotherapy.” Raymond […]. .
Immuno-Oncology News 08/16/2019 10:15
ADXS-NEO, an investigational cancer immunotherapy, induced an immune response against 90% of all cancer targets in a patient with metastatic microsatellite stable colorectal cancer (MSS-CRC), data from an ongoing Phase 1 trial show. ADXS-NEO, jointly developed by Advaxis and Amgen, is a new type of personalized cancer immunotherapy that works by helping a patient’s immune […]. .

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications